MaxCyte (MXCT) Stock Statistics & Valuation Metrics

MaxCyte has a market cap or net worth of $131.76M. The enterprise value is $123.98M.

MaxCyte has 107,121,670 shares outstanding. The number of shares has decreased by -2.65% in one year.

MaxCyte’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -23.87%.

The current PE Ratio of MaxCyte is ―. MaxCyte’s PEG ratio is -0.48.

In the last 12 months, MaxCyte had revenue of 33.03M and earned -44.63M in profits. Earnings per share was -0.42.

In the last 12 months, operating cash flow was -28.17M and capital expenditures -1.34M, giving a free cash flow of -29.50M billion.

MaxCyte pays an annual dividend of ―, resulting in a dividend yield of ―

MaxCyte upcoming earnings date is Aug 12, 2026, TBA (Confirmed).

MaxCyte as a current ratio of 8.30, with Debt / Equity ratio of 10.42%

In the past 12 months, MaxCyte has paid 0.00 in taxes.

MaxCyte EV to EBITDA ratio is -4.12, with an EV/FCF ratio of -4.50.

MaxCyte has $14.56M in cash and marketable securities with $17.49M in debt, giving a net cash position of -$2.93M billion.

Gross margin is 80.70%, with operating margin of -137.12%, and net profit margin of -135.14%.

The average price target for MaxCyte is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy